RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer

RASEFは肺癌の新たな診断マーカー及び治療標的である

Oshita Hideto

Genome-wide gene expression profile analyses revealed that Ras and EF-hand domain containing (RASEF) was significantly transactivated in the majority of lung cancers. Transient expression of RASEF promoted cell growth, whereas transfection of siRNA for RASEF to lung cancer cells reduced its expression and resulted in growth suppression of the cancer cells. Immunohistochemical staining using tumor tissue microarrays consisting of 341 archived non-small cell lung cancers revealed the association of strong RASEF positivity with poor prognosis (P = 0.0034 by multivariate analysis). RASEF could bind to extracellular signal-regulated kinase (ERK) 1/2 and appeared to enhance the ERK1/2 signaling. In addition, inhibition of interaction between RASEF and ERK1/2 using cell-permeable peptide that corresponded to the ERK1/2-interacting site of RASEF protein, suppressed growth of lung cancer cells. RASEF may play important roles in lung carcinogenesis, and could be useful as a prognostic biomarker and a target for the development of new molecular therapies.

oncogenes

cancer antigen

biomarker

therapeutic target

lungcancer

Medical sciences [ 490 ]

eng

Copyright(c) by Author

[Created] 2014-11-21

Hideto Oshita, Ryohei Nishino, Atsushi Takano, Takashi Fujitomo, Masato Aragaki, Tatsuya Kato, Hirohiko Akiyama, Eiju Tsuchiya, Nobuoki Kohno, Yusuke Nakamura, Yataro Daigo; RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer; Molecular Cancer Research, Published OnlineFirst May 16, 2013. (doi: 10.1158/1541-7786.MCR-12-0685-T) references

[DOI] http://dx.doi.org/10.1158/1541-7786.MCR-12-0685-T references

広島大学